SNPs | Control (N = 192) | Injured Group (N = 146) | P – valuea | Adjusted OR (CI 95%)b | Non-contact ACL (N = 67) | P – valuea | Adjusted OR (CI 95%)c |
---|---|---|---|---|---|---|---|
N (%) | N (%) | ||||||
COL1A1 | |||||||
rs1107946e | |||||||
GG | 110 (57.9) | 92 (63.4) | 0.71 | 1d | 45 (67.2) | 0.69 | 1d |
GT | 65 (34.2) | 43 (29.7) | 0.82 (0.47–1.40) | 17 (25.3) | 0.77 (0.37–1.57) | ||
TT | 15 (7.9) | 10 (6.9) | 1.10 (0.43–2.81) | 5 (7.5) | 1.22 (0.37–3.94) | ||
G | 285 (75.0) | 227 (78.3) | 0.96 | 1d | 107 (79.9) | 0.93 | 1d |
T | 95 (25.0) | 63 (21.7) | 0.99 (0.65–1.50) | 27 (20.1) | 1.02 (0.59–1.78) | ||
COL1A2 | |||||||
rs412777f | |||||||
AA | 77 (41.0) | 67 (46.2) | 0.33 | 1d | 30 (44.8) | 0.40 | 1d |
AC | 87 (46.3) | 62 (42.8) | 0.81 (0.48–1.36) | 31 (46.3) | 1.03 (0.53–1.99) | ||
CC | 24 (12.8) | 16 (11.0) | 0.55 (0.25–1.24) | 6 (8.9) | 0.49 (0.17–1.47) | ||
A | 241 (64.1) | 196 (67.6) | 0.16 | 1d | 91 (67.9) | 0.34 | 1d |
C | 135 (35.9) | 94 (32.4) | 0.77 (0.53–1.11) | 43 (32.1) | 0.80 (0.50–1.28) | ||
rs42524g | |||||||
GG | 128 (67.0) | 88 (60.7) | 0.26 | 1d | 41 (61.2) | 0.09 | 1d |
GC | 59 (30.9) | 48 (33.1) | 1.22 (0.73–2.04) | 21 (31.3) | 1.19 (0.60–2.35) | ||
CC | 4 (2.1) | 9 (6.2) | 2.85 (0.76–10.75) | 5 (7.5) | 5.73 (1.22–26.95) | ||
G | 315 (82.5) | 224 (77.2) | 0.17 | 1d | 103 (76.9) | 0.10 | 1d |
C | 67 (17.5) | 66 (22.8) | 1.35 (0.88–2.06) | 31 (23.1) | 1.57 (0.92–2.69) | ||
rs2621215f | |||||||
TT | 116 (61.7) | 78 (53.8) | 0.18 | 1d | 35 (52.2) | 0.06 | 1d |
TG | 64 (34.0) | 56 (38.6) | 1.38 (0.83–2.30) | 25 (37.3) | 1.32 (0.67–2.59) | ||
GG | 8 (4.3) | 11 (7.6) | 2.36 (0.83–6.68) | 7 (10.4) | 4.29 (1.26–14.61) | ||
T | 296 (78.7) | 212 (73.1) | 0.08 | 1d | 95 (70.9) | 0.04 | 1d |
G | 80 (21.3) | 78 (26.9) | 1.42 (0.96–2.13) | 39 (29.1) | 1.69 (1.02–2.81) |